01

What saffron is and why it matters

Saffron (Crocus sativus) is the dried stigma of the crocus flower, used for centuries in traditional medicine. The bioactive compounds that matter clinically are crocin (responsible for the colour and most of the mood effects) and safranal (responsible for the aroma and additional neuroactive effects).³

Modern interest in saffron for menopause started with depression research. Saffron extracts consistently outperformed placebo for depression and anxiety in non-menopausal populations.⁴ Researchers then asked: does this hold up in perimenopause, when mood symptoms are common and many women want to avoid antidepressants?

The answer, repeated across multiple trials now, is yes.

02

The evidence for mood and sleep

Mood and anxiety

The strongest individual trial is the Lopresti and Smith 2021 study from Australia.¹ 86 perimenopausal women aged 40–60 received either 14 mg twice daily of a standardised saffron extract (affron) or placebo for 12 weeks. The saffron group showed:

• 33% reduction in HAM-A anxiety scores (compared to 11% for placebo)
• 32% reduction in PHQ-9 depression scores (compared to 13% for placebo)
• Significant improvement in psychological symptoms on the Greene Climacteric Scale

A 2025 meta-analysis comparing saffron directly against SSRIs (a common antidepressant class) found no significant difference in effectiveness for depression or anxiety, with saffron producing fewer adverse events.²

Sleep

Smaller trials show saffron improves sleep latency (time to fall asleep) and total sleep quality, including in perimenopausal women specifically.⁵ The effect is moderate, not dramatic. Best results come from taking saffron in the evening, with consistent daily use over at least 4 weeks.

What this means in practice

If your primary perimenopausal symptoms are mood-related (low mood, anxiety, irritability, mild sleep disturbance), the case for trialling saffron is strong. Expected timeline to meaningful effect: 4–8 weeks of consistent daily use.

03

What saffron does NOT do well

This is where most marketing overstates the evidence.

Hot flushes and night sweats

The Lopresti 2021 trial measured vasomotor symptoms (hot flushes, night sweats) as a secondary outcome. Saffron did not produce a statistically significant improvement compared to placebo for vasomotor symptoms.¹ Other trials show similar results: small or null effects on hot flushes specifically.

If your primary complaint is hot flushes, shatavari has more direct evidence, and MHT or non-hormonal prescription options (gabapentin, SSRIs at low dose) produce larger and faster improvements than any supplement.

Vaginal dryness

Saffron has no meaningful evidence for genitourinary symptoms. See Vaginal Dryness Explained for what actually works for those.

Joint pain or bone health

No evidence base for these uses.

04

Dose, form, and what to look for

The clinical trials used specific standardised extracts, not generic saffron threads from the spice rack. Cooking-grade saffron at the doses needed for clinical effect would be both very expensive and inconsistent in active compound content.

What to look for on a label

• Standardised extract (e.g., affron, Safr'Inside) at a dose used in clinical trials
• 28 mg total daily dose of standardised extract, split as 14 mg twice daily or 28 mg in a single dose (the Lopresti trial used 14 mg twice daily)
• Standardised to safranal content (typically 0.3–0.4%)
• Australian TGA-listed (AUST L number)
• Third-party tested for purity (saffron is sometimes adulterated with marigold or turmeric)

Avoid

• Products that list "saffron" with no dose specified
• "Proprietary blends" that hide the saffron amount
• Generic saffron powder marketed as a supplement without standardisation

The active dose matters. Sub-therapeutic saffron is one of the more common reasons women report "trying saffron without effect".

05

Who it suits, who should skip it

Good candidates

• Mood, anxiety, or sleep symptoms are your primary perimenopausal concern
• You want to trial a non-hormonal option first
• You cannot tolerate or have contraindications to SSRIs
• You are willing to give it 8–12 weeks at the right dose before judging

Skip or wait

• Hot flushes are your main complaint (shatavari or MHT is a better fit)
• You are already on antidepressants — saffron should not be combined without medical supervision (theoretical risk of serotonin syndrome)
• You are pregnant or breastfeeding (high doses are contraindicated)
• You are on blood thinners (saffron has mild antiplatelet effect at high doses)

Always check with your GP first if

• You are on prescription medication, particularly antidepressants, antihypertensives, or blood thinners
• You have bipolar disorder (any mood-active compound needs medical oversight)
• You are scheduled for surgery (stop two weeks prior)

06

When MHT is the more honest answer

For women with significant menopausal symptoms across multiple domains (hot flushes plus mood plus sleep plus joint pain), MHT typically produces larger and faster improvements than any single supplement, including saffron. The Australasian Menopause Society publishes plain-English guidance on candidacy.

Saffron remains useful in two scenarios alongside MHT consideration:

• Mild-to-moderate perimenopausal mood symptoms where MHT is not yet warranted or not yet chosen
• Residual mood symptoms in women on MHT whose other symptoms have improved

The most useful frame: saffron is a well-evidenced tool for a specific symptom (mood, anxiety, sleep). It is not a general menopause cure. Used for what it does well, the evidence is solid. Used for what it does not do, it will disappoint.

For more on raising treatment options with your GP, see Own Your Menopause Appointment: 5 Tips from a GP. For the broader supplements landscape, see Menopause Supplements Guide.